Biofrontera (BFRI) announced the successful database lock of two clinical studies evaluating Ameluz PDT, marking an important milestone ahead of several anticipated data and regulatory events in 2026. The databases for the treatment phase of the Company’s Phase 3 clinical study evaluating Ameluz PDT for the treatment of actinic keratosis on the extremities, neck and trunk as well as its Phase 2 clinical study evaluating the treatment of moderate to severe acne vulgaris were successfully locked on January 5, 2026. All data from participants that is collected throughout each study is captured in a specific database. Locking the database enables unblinding and statistical analysis of the study results in accordance with the pre-specified study endpoints. Biofrontera expects data for both studies to be available in February of this year.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BFRI:
- Biofrontera Receives Nasdaq Notice on Bid Price Noncompliance
- Biofrontera completes transfer of Ameluz, RhodoLED FDA approval
- Biofrontera Inc. files to sell 4M shares of common stock for holders
- Biofrontera completes final patient visit in Phase 1 PK study of Ameluz gel
- Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC